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Abstract
Background: Choosing cost-effective strategies for improving the health of the public is difficult
because the relative effects of different types of interventions are not well understood. The benefits
of one-shot interventions may be different from the benefits of interventions that permanently
change the probability of getting sick, recovering, or dying. Here, we compare the benefits of such
types of public health interventions.
Methods:  We used multi-state life table methods to estimate the impact of five types of
interventions on mortality, morbidity (years of life in fair or poor health), and years of healthy life
(years in excellent, very good, or good health).
Results: A one-shot intervention that makes all the sick persons healthy at baseline would increase
life expectancy by 3 months and increase years of healthy life by 6 months, in a cohort beginning at
age 65. An equivalent amount of improvement can be obtained from an intervention that either
decreases the probability of getting sick each year by 12%, increases the probability of a sick person
recovering by 16%, decreases the probability that a sick person dies by 15%, or decreases the
probability that a healthy person dies by 14%. Interventions aimed at keeping persons healthy
increased longevity and years of healthy life, while decreasing morbidity and medical expenditures.
Interventions focused on preventing mortality had a greater effect on longevity, but had higher
future morbidity and medical expenditures. Results differed for older and younger cohorts and
depended on the value to society of an additional year of sick life.
Conclusion: Interventions that promote health and prevent disease performed well, but other
types of intervention were sometimes better. The value to society of interventions that increase
longevity but also increase morbidity needs further research. More comprehensive screening and
treatment of new Medicare enrollees might improve their health and longevity without increasing
future medical expenditures.
Published: 5 April 2007
BMC Public Health 2007, 7:52 doi:10.1186/1471-2458-7-52
Received: 4 May 2006
Accepted: 5 April 2007
This article is available from: http://www.biomedcentral.com/1471-2458/7/52
© 2007 Diehr et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
Page 2 of 15
(page number not for citation purposes)
Background
The primary emphasis in public health is on health pro-
motion and disease prevention [1], but the situations
where this is the most effective approach are not always
clear. It is important to understand which strategies pro-
vide the most benefit to society so that limited resources
can be used effectively. There are many conceptual frame-
works for the social and behavioral determinants of
health, such as that proposed by the Institute of Medicine
[1] or Evans and Stoddart [2]. There are individual-level
theories about health interventions such as the Health
Belief Model [3] and the Transtheoretical Model [4]. There
are also community or group-level theories that include
ecological perspectives [5], community organization [6],
and social marketing [7]. None of these theories, however,
directly addresses the orientation toward prevention ver-
sus treatment for different populations [8]. That is,
whether it is more effective to keep healthy persons
healthy, to return sick persons to health, to keep sick per-
sons from dying, or to keep healthy persons from dying.
Figure 1 represents "the public" as belonging to one of
three states: healthy, sick, or (when followed over time)
dead. The arrows indicate that persons can change states.
The probabilities of transitioning to the various states one
year later are shown for age 65. For example, using stand-
ard probability notation, P(S|H) = .09 indicates that the
probability of a 65-year-old person being sick next year,
given that he is healthy this year, is .09. In Figure 1, health
promotion and disease prevention can be thought of pri-
marily as decreasing the probability that healthy persons
become sick, P(S|H). However, decreasing the probability
that healthy or sick persons die (P(D|H) or P(D|S)), or
increasing the probability that sick persons return to
health (P(H|S)) would also improve the health of the
public. How might these approaches differ in achieving
public health goals?
Figure 1 may be thought of as a system with three states,
healthy, sick and dead. The status of a system at any time
is completely defined by its initial conditions (the
number of healthy and sick persons at baseline) and the
probabilities of transition to a different state. Public
health interventions may thus attempt to improve health
by changing the initial conditions, by modifying the tran-
sition probabilities, or both.
Initial conditions could be improved by moving some of
the persons from sick to healthy at baseline (referred to
later as the One-Shot  intervention). An intervention
could also aim to change the transition probabilities at
each year of age. Such an intervention might decrease
P(S|H), the probability that healthy persons become sick,
through health promotion or disease prevention pro-
grams (HP/DP). Improved methods of and access to treat-
ment can increase P(H|S), the probability that sick
persons return to health (Treatment). Interventions such
as improved ICU care may lower P(D|S), the probability
that sick persons die (ICU). Finally, interventions to
improve traffic, gun, or workplace safety could reduce
P(D|H), the probability of death for healthy persons
(Safety). One might also combine interventions, such as
HP/DP + One-Shot, or HP/DP + ICU. Such interventions
are likely to have different effects on longevity or years of
life (YOL), years of healthy life (YHL), morbidity or years
of sick life (YSL), and on medical expenditures.
The intervention types are defined formally in Table 1,
which provides an algebraic, a text, and a mnemonic
description for each type of intervention. The One-Shot
intervention moves all of the sick persons to the healthy
state, only once, at baseline. To allow for less potent inter-
ventions, we define One-Shot as an intervention that
moves 100*λ% of the sick persons healthy at baseline
only, where the parameter λ has a value less than or equal
to one. The four interventions that improve the transition
probabilities at every age are described algebraically as a
function of a parameter, α, which is the amount of
"improvement" in the relevant age-specific transition
probability. For example, HP/DP is an intervention that
multiplies P(S|H) by (1-α); to achieve a 10% improve-
ment, α = 0.10, and P(S|H) is multiplied by 0.9, thus low-
ering the probability that a healthy person becomes sick
by 10% at every age.
The names given to the intervention types do not refer to
real interventions, but were chosen to help readers
remember the intervention's primary feature. Consider a
public health intervention that delivers antibiotics to a
population. If the antibiotics are administered at one time
only to a subset (possibly all) of the sick persons, with the
goal of making 100*λ% of the sick persons immediately
healthy, that would be a One-Shot intervention, with its
strength measured by λ. If antibiotics are provided every
year to a subset of the sick persons, with the goal of
increasing the proportion of sick persons who are healthy
one year later by a factor of (1+α), that would be a Treat-
ment, with its strength measured by α. Antibiotics given
every year to a sample of the sick persons to lower their
probability of dying would be an ICU-type intervention.
And antibiotics administered every year to a sample of the
healthy persons would be a HP/DP or a Safety-type inter-
vention depending on whether the primary goal was to
prevent sickness or to prevent death. The antibiotic pro-
gram would thus be classified differently depending on
the targets, the timing and the major intended effect. More
detailed examples are presented in the discussion section.
The goal of this paper is to compare the effects of the dif-
ferent types of intervention strategies on years of life, yearsBMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
Page 3 of 15
(page number not for citation purposes)
of healthy life, and years of sick life (YOL, YHL, YSL) and
on medical expenditures. We hypothesized that the HP/
DP intervention would perform well, because prevention
is the preferred strategy in public health. There may be sit-
uations, however, where prevention is not the best
approach, because the effectiveness of an intervention
depends on the nature and strength of the intervention,
on the initial health and age of the target population, and
on the value that society places on an additional year of
sick life.
Methods
Health states and transition probabilities
We defined "healthy" as being in excellent, very good, or
good health and "sick" as being in fair or poor health. Age-
specific transition probabilities among the states were cal-
culated from three large datasets, as explained in Appen-
dix 1 and in more detail elsewhere [9]. Multi-state life
tables were calculated from the transition probabilities.
Based on initial conditions (the number of healthy and
sick persons at baseline) and the transition probabilities,
the life table provides estimates of the future years of
healthy life (years spent in the healthy state) from base-
line to age 100. An example of such calculations is given
in Appendix 1. National estimates of the proportion of
older adults who were healthy or sick at ages 0 and 65
came from the National Health Interview Survey [10].
Data on medical expenditures by age and health state
were estimated from MEPS data collected in 2002, using
the MEPSnet software [11]. These data were used to esti-
mate future medical expenditures for each intervention.
One-Year Transitions Among Three Health States for Age 65 Figure 1
One-Year Transitions Among Three Health States for Age 65. P(A | B) is the probability of being in state A at age 66 
for a person who is in state B at age 65. For example, P(S|H) is the probability that a healthy 65-year-old will be sick at age 66. 
The quantities in parentheses represent the generic interventions that would affect the relevant transition probability, as fol-
lows. HP/DP is health promotion and disease prevention, which affects the probability that healthy persons become sick. 
Treatment makes sick persons healthier. The ICU reduces the probability that sick persons die. The Safety intervention 
reduces the chance that healthy persons die.
Healthy 
P(H|H)=.90
Dead
Sick
P(S|S)=.62
P(S|H)=.09 
(HP/DP)
P(H|S)=.33 
(Treatment)
P(D|H)=.01 
(Safety)
P(D|S)=.05 
(ICU)BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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Interventions
We examined the performance of the types of intervention
listed in Table 2. The "Status Quo" intervention made no
change and is the basis for comparison. "One-Shot" is an
intervention that moves 100*λ% of the sick persons to the
healthy category at baseline only (λ is set to 1 in most of
this paper). We also defined four hypothetical interven-
tions, each of which affects exactly one of the transition
probabilities in Figure 1. We calculated the effect of
"improving" each of the transition probabilities by
100*α%. This improvement is defined as either multiply-
ing P(H|S) by 1+ α (to increase the probability of recov-
ery), or multiplying P(S|H), P(D|H), or P(D|S) by 1-α (to
decrease the probability of getting sick or dying). In most
of this paper, α is set to 0.10. We also evaluated the two
combined interventions shown in Table 2, and compared
each intervention to the "Status Quo" intervention.
The worth of an additional YHL or YSL
Consider two hypothetical interventions, A and B. Inter-
vention A produces 4 additional years of healthy life and
no additional years of sick life, while B produces 3 addi-
tional YHL and 2 additional YSL. Which intervention is
better? The answer depends on the worth to society of an
additional YHL or YSL. Worth might be measured in dol-
lars (perhaps based on lost productivity or on higher med-
ical expenditures for sick persons), or in some other way.
Suppose we knew that an additional YHL was worth 100
"units" to society, and an additional YSL was worth 0;
then intervention A would be preferred because it pro-
vided 400 units of worth compared to 300 for interven-
tion B. Alternatively, if a YSL was worth 50, the two
interventions would be equivalent because both would
provide 400 units of worth. If a YSL was worth 100, there
would be no distinction between YHL and YSL, and Inter-
vention B would be preferred. We do not know the values
for absolute worth (or even the units in which it should be
measured), but we can think productively about the rela-
tive worth of a YSL and a YHL. Let β be the ratio of the
worth of an additional YSL to the worth of a YHL. In the
3 cases above, β = 0/100 = 0, = 50/100 = 0.5, and = 100/
100 = 1.0, respectively.
The best intervention will provide the most incremental
worth to society for a given input. We assume that the
worth of future years of life is K*(YHL + β*YSL) worth-
adjusted years, where β is a number less than or equal to
1 and K is some constant that can be ignored with no loss
of generality. If β = 1, future worth is YHL+1*YSL = YOL;
society is indifferent to whether the person is in the
healthy or sick state, and would seek to maximize life
expectancy. If β = 0, future worth = YHL+0*YSL=YHL;
Table 1: Interventions, Parameters, and Terms
Algebraic Descriptive Mnemonic Label
Interventions
No Intervention No Change Status Quo
Change the Initial Conditions:
Let π' be π + λ(1 - π)M o v e  1 0 0 * λ% of the sick persons to healthy, at baseline only. One-Shot
Improve the Probabilities:
P(S|H) * (1-α) At every age, lower the probability of a healthy person getting sick by a factor of (1-α), 
perhaps through such health promotion and disease prevention activities as smoking 
prevention programs or vaccinations
HP/DP
P(D|H) * (1-α) At every age, lower the probability that a healthy person dies, perhaps by improving 
automobile, workplace, or gun safety.
Safety
P(D|S) * (1-α) At every age, lower the probability that a sick person dies, perhaps by improving intensive 
care units.
ICU
P(H|S) * (1+α) At every age, increase the probability that a sick person becomes healthy, possibly by 
improving treatment.
Treatment
Parameters
λ Proportion of sick persons moved instantaneously to the healthy state by the One-Shot 
intervention (usually set to 1.0)
α Amount of improvement to a transition probability (usually set to 0.1)
β Worth to society of an additional YSL divided by worth of an addition YHL (usually set to 
0.5)
Relative Worth
π Proportion who are healthy at baseline (usually set to 0.98 for birth cohort and 0.80 for 
retiree cohort)
Outcomes
YHL Years of healthy life (years in excellent, very good, or good health) YHL
YSL Years of sick life (years in fair or poor health) YSL
YHL + β*YSL Worth-adjusted years of life WorthBMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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society is indifferent to the sick and dead states, and the
intervention that maximizes years of healthy life would
provide the most worth. Negative values of β imply that
sickness is a state worse than death [12]. We examined a
range of β between -0.25 and 1.0. For each pair of inter-
ventions we calculated the intervention costs at which one
intervention would be more cost-effective than the other,
as explained below.
Analysis
We first estimated the effect of each intervention, with λ =
1.0 and α = 0.10. For the HP/DP+One-Shot intervention,
we moved all sick persons to the healthy state at baseline
and also improved P(S|H) by α. For HP/DP+ICU, we
improved both P(S|H) and P(D|S) by α. We estimated the
YOL, YHL, and YSL for a cohort of size 100,000 at base-
line, using multi-state life table software implemented in
Stata [13]. This was done for both a Birth cohort (from age
0 to 100) and a Retiree cohort (from age 65 to 100). We
also estimated average lifetime medical expenditures as
the number of persons projected to be in each health state
at each age multiplied by the average medical expenditure
for that state and age, summed and divided by 100,000.
Standardizing the comparisons
A comparison of interventions requires that we standard-
ize the input or the output. For example, when interven-
tions are compared on their cost per quality-adjusted life
year, cost is the input and QALY is the output. Here, we
will use incremental worth to society (improvement in
worth-adjusted years of life) as the output, and account
for input in two ways. We first examine the amount of
output produced with a fixed input, α. Because One-Shot
is not a function of α, we also examine the size of input
(α) required to produce a fixed output, defined as the
same output as the One-Shot intervention. This is
explained in more detail below.
Results
Figure 2 shows the transition probabilities from age 0 to
100. These were estimated from three large longitudinal
datasets, as explained in Appendix 1 and are listed in more
detail elsewhere [9]. For example, the topmost line shows
the probability that a person who is healthy at the age on
the X axis will be healthy one year later, (P(H|H)). The
lowest lines are the probabilities of getting sick or dying.
The probabilities are quite favorable below about age 40,
but after that the probability of remaining or becoming
healthy declines and the probability of sickness or death
increases. The interventions that improve the probabili-
ties would raise the P(H|S) line by 10%, or lower the three
bottom lines by 10%.
Table 2: Outcomes* by Baseline State by Cohort
All Healthy at Baseline All Sick at Baseline US Distribution at Baseline **
12 3 4 5 6 7 8 9 1 0
Intervention YHL YSL YOL YHL YSL YOL YHL YSL YOL
Birth Cohort
Status Quo 67.87 9.51 77.38 64.52 9.94 74.46 67.80 9.52 77.33
One-Shot 67.87 9.51 77.38 67.87 9.51 77.38 67.87 9.51 77.38
HP/DP 68.97 8.81 77.78 65.57 9.27 74.84 68.90 8.82 77.72
Treatment 68.72 8.96 77.69 65.55 9.31 74.86 68.66 8.97 77.63
ICU 68.20 9.77 77.97 65.09 10.23 75.32 68.14 9.78 77.92
Safety 68.24 9.63 77.87 64.87 10.06 74.92 68.17 9.64 77.81
HP/DP+One-Shot 68.97 8.81 77.78 68.97 8.81 77.78 68.97 8.81 77.78
HP/DP+ICU 69.29 9.05 78.34 66.13 9.54 75.67 69.22 9.06 78.28
Retiree Cohort
Status Quo 13.12 4.28 17.40 10.44 5.45 15.90 12.58 4.52 17.10
One-Shot 13.12 4.28 17.40 13.12 4.28 17.40 13.12 4.28 17.40
HP/DP 13.62 4.02 17.64 10.84 5.24 16.09 13.07 4.26 17.33
Treatment 13.43 4.12 17.55 10.94 5.20 16.14 12.93 4.34 17.27
ICU 13.30 4.50 17.79 10.71 5.71 16.43 12.78 4.74 17.52
Safety 13.36 4.38 17.74 10.64 5.53 16.17 12.82 4.61 17.43
HP/DP+One-Shot 13.62 4.02 17.64 13.62 4.02 17.64 13.62 4.02 17.64
HP/DP+ICU 13.80 4.22 18.01 11.12 5.49 16.60 13.26 4.47 17.73
* Years of healthy life, years of sick life, and Years of life due to a 10% improvement (α = .10) using the listed intervention. For One-Shot, the 
intervention makes everyone healthy at baseline (λ= 1.0 and α is irrelevant). For HP/DP+One-Shot, everyone is healthy at baseline and α = .10 for 
the HP/DP intervention).
** U.S. distribution at baseline is assumed to be 98% healthy at birth (π = .98) and 80% healthy at age 65 (π = .80). Column 8 is calculated as 
π*(column 2) plus (1 - π)*(column 5).BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
Page 6 of 15
(page number not for citation purposes)
Figure 3 shows the number of persons in a Birth cohort
who are predicted to be healthy or sick at each age. (The
number dead is not shown). The solid lines represent a
Birth cohort of 100,000 persons where everyone was
healthy at birth; the upper line is the number who are
healthy over time and the lower line solid line is the
number who are sick. The dashed lines represent a cohort
where everyone was sick at birth. The One-Shot interven-
tion modifies the percent initially healthy or sick. Note
that even in the "all sick at birth" cohort, most persons are
healthy after a few years because P(H|S) is high at the
younger ages (see Figure 2). Importantly, until about age
80 the number of sick persons is small relative to the
number who are healthy. This will have consequences for
the effectiveness of the various interventions.
The areas under the two "# healthy" curves are the
expected years of healthy life (YHL), and differ for the two
cohorts primarily because of the differences near age zero.
The line labeled "Status Quo" in Table 2 (explained
below) indicates that YHL is 67.87 years if everyone is
healthy at birth, and 64.52 years if everyone is sick at
birth. The area under the "# sick" curves is years of sick life
(YSL) or morbidity. A third pair of (dotted) lines repre-
sents the number healthy and sick if 98% of the popula-
tion is healthy at birth, similar to national estimates. In
Figure 3, these lines are virtually indistinguishable from
the "all healthy at birth" lines. YHL is 67.80 years.
Figure 4 presents the same information, but for the Retiree
cohort. As before, the two solid lines are the number
healthy (upper line) and sick (lower line) when all are
healthy at age 65. The two dashed lines are the number
healthy and sick when all are sick at age 65. The two dot-
ted lines reflect the number sick and healthy when 80%
are healthy and 20% are sick at age 65, similar to national
estimates. Note that the initial conditions (all sick versus
all healthy versus 80% healthy at age 65) are more impor-
tant than they were in Figure 3. The number of healthy
people eventually becomes similar for all initial condi-
tions, but it takes longer than in Figure 3. It is clear that the
areas under the three top curves are different. YHL is esti-
mated as 13.12 years if all are healthy at age 65, 10.44
years if all are sick, and 12.58 years if 80% are healthy.
Table 2 shows the estimated years of healthy life, years of
sick life, and years of life for each intervention, by cohort,
and depending on whether the cohort was all healthy
(columns 2–4) or all sick (columns 5–7) at baseline. For
example, the first line shows that under the Status Quo,
persons in the Birth cohort who are healthy at birth aver-
age 67.87 healthy years and 9.51 sick years, summing to
77.38 years of life (life expectancy). Values for persons
sick at baseline are shown next, and are less favorable
(e.g., only 74.46 YOL). In columns 8–10, the percent
healthy and sick at baseline are set to the national values:
98% initially healthy and 2% sick for the Birth cohort, and
80% healthy and 20% sick for the Retiree cohort. For
example, for the Birth cohort, Column 8 is .98*(column
2) plus .02*(column 5).
The second line of Table 2 shows results for the One-Shot
intervention. Note that the outcomes for the initially
healthy cohort are identical to the Status Quo outcomes
(because One-Shot did not affect those already in the
healthy state) and that the outcomes for the sick cohort
are identical to those for the initially healthy cohort,
because all sick persons were moved to the healthy state at
baseline. Similarly, results for HP/DP+ One-Shot are the
same as HP/DP alone when all are healthy at baseline.
Note that all of the interventions produce more YHL and
YOL than the Status Quo, in both the Birth and Retiree
cohorts.
Incremental change in YHL, YSL, YOL, and medical 
expenditures
Columns 2, 3, and 4 of Table 3 are the same as the last
three columns of Table 2, except that the value for the Sta-
tus Quo has been subtracted from each line. For example,
dYHL (difference in YHL) is 0 for the Status Quo interven-
tion, by definition. The One-Shot intervention achieved
0.067 additional years of healthy life in the Birth cohort,
which is the entry in the second row of Table 3. One-Shot
also decreased YSL (years of sick life, or morbidity) by
0.009 years and increased YOL (survival) by 0.059 years.
The effects of the One-Shot intervention were larger in the
Retiree cohort. Column 5 shows the estimated difference
in future medical expenditures attributable to the inter-
vention, in dollars. All of the interventions improved YHL
and YOL (dYHL and dYOL are always positive), although
the improvement was not usually large. The Safety and
ICU interventions increased both morbidity (dYSL) and
medical expenditures (d$), while the other interventions
decreased them. HP/DP + ICU decreased YSL but
increased medical expenditures nonetheless. The entries
in columns 2–5 of Table 3 were calculated for α = .10.
However, we discovered that the amount of change in
YHL, YSL, and YOL was approximately a linear function of
α through the origin for |α| < .3 (except for One-Shot and
HP/DP + One-Shot which do not depend specifically on
α). This simplification is used later on to extend the stand-
ard configuration to other values of α.
Relative Effectiveness of an Intervention
Interventions differ in their effect on YOL, YHL, and YSL.
We assume that the incremental worth to society of an
intervention is K*(dYHL + β* dYSL), where K is a constant
that can be ignored here, and β is the relative worth of an
additional YSL. First, assume that β = 0.5 (that an addi-
tional YSL is worth half as much to society as an addi-BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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tional YHL). Column 6 of Table 3 shows the incremental
number of worth-adjusted years for each intervention, cal-
culated as dYHL+.5*dYSL. In the Birth cohort the two
combined interventions provide the most worth, fol-
lowed by HP/DP. Results are similar for the Retiree cohort
except that One-Shot is the best simple intervention.
Worth to society may also be calculated for other values of
β (see Appendix 2). For example, if β = 0, the worth is sim-
ply dYHL, and if β = 1 the worth is dYOL. Interventions
that decrease YSL produce more worth if β is low, and
interventions that increase YSL are favored if β is high. In
the Birth cohort, HP/DP produced the most worth of all
the single interventions if β <0.798, and ICU was most
effective for higher values of β (calculations not shown).
In the Retiree Cohort, the One-Shot intervention provided
the most worth for β <0.741, and the ICU intervention
was better for higher values of β. HP/DP was better than
ICU for β < 0.606. Thus, the "best" intervention depends
strongly on β, the relative worth to society of an addi-
tional YSL.
Although Column 6 allows us to compare the worth of
interventions that were all improved by the same factor, α
= .10, the One-Shot intervention is not a function of α,
and so cannot fairly be compared to the others. To
improve comparability, column 7 shows the value of α
that would be needed for each intervention to produce the
One-year Transition Probabilities Figure 2
One-year Transition Probabilities.
1 AGE
100 90 80 70 60 50 40 30 20 10 0
P
r
o
b
a
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t
y
1.00
.80
.60
.40
.20
0.00
P(H|H)
P(S|S)
P(H|S)
P(S|H)
P(D|S)
P(D|H)
P(H|H)
P(S|S) P(H|S)
P(S|H)
P(D|S)
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same number of worth-adjusted years as the One-Shot
intervention. For example, in column 6 of Table 3 for the
Retirees, the worth of One-Shot is .4180 and the worth of
HP/DP is only .3590. To increase the worth of HP/DP to
the One-Shot level, we must multiply its worth by .4180/
.3590 = 1.164. Because incremental worth was found to
be a linear function of α through the origin, the α that will
achieve this change is 1.164 * .10 = .1164, which is tabled
in Column 7. In the Birth cohort, One-Shot is equivalent
to an α of about 0.01, while in the Retiree cohort it is
equivalent to α between 0.1 and 0.2. Lower values in Col-
umn 7 are preferred, because they indicate that a smaller
dose of the row intervention is needed to be equivalent to
the One-Shot intervention. In both cohorts, HP/DP is the
best single intervention that modifies probabilities and
HP/DP + ICU is the best over-all intervention, in the sense
of achieving the specified worth with the smallest amount
of change in the transition probability (the smallest value
of α).
Column 7 shows the required α when the initial condi-
tions are the same as the U.S. population, and β = 0.5.
Estimated # of healthy and sick persons over time in Birth cohort (All healthy, All sick, or 98:2 ratio at Birth)* Figure 3
Estimated # of healthy and sick persons over time in Birth cohort (All healthy, All sick, or 98:2 ratio at Birth)*. 
*The topmost solid line is the number healthy when all were healthy at baseline, and the lower solid line is the number sick 
when all were healthy at baseline. The two dashed lines represent the number healthy and sick when all were sick at baseline. 
A third pair of dotted lines represent the number healthy and sick when 98% were healthy at baseline, but cannot be seen in 
this figure because they are essentially identical to the solid lines.
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More generally, if π is the proportion who are healthy at
baseline,
where dYHLHj denotes the change in YHL caused by inter-
vention j if everyone is healthy at baseline, dYHLSj is the
change if everyone is sick at baseline, and dYHLH1 and
dYHLS1 refer to the One-Shot intervention. This equation
was used to calculate the required α for different combi-
nations of π and β. Table 4 indicates which of the simple
interventions has the lowest required α for different val-
ues of π and β. For the birth cohort, HP/DP is best for β <
0.4, ICU is best for β > 0.7, and HP/DP is preferred to ICU
for higher values of π for β between .4 and 0.7. For the
Retiree cohort, the Treatment intervention is preferred
when both β and π are low; that is, when the initial pop-
ulation is less then 40% healthy and the relative worth of
an additional YSL is low. The preferred interventions for
negative values of β were the same as those for β = 0, and
are not shown separately. Table 4 thus shows that HP/DP
is not always the best intervention, although under the
standard configuration (π = .98 or .80, β = .5) HP/DP
would be preferred. For different values of π or β, an ICU
or a Treatment intervention might be preferable. The
α
πβ πβ
π
required
HH SS dYHL dYSL dYHL dYSL
=
+∗ +− +∗ ∗ [ ( ) ( )( )] . 11 1 1 11 0
( () ( ) ( )
,
dYHL dYHL dYHL dYSL Hj Hj Sj Sj +∗ +− +∗ βπ β 1
Estimated # of healthy and sick persons over time in Retiree cohort (All healthy, All sick, or 80:20 ratio at Age 65)* Figure 4
Estimated # of healthy and sick persons over time in Retiree cohort (All healthy, All sick, or 80:20 ratio at Age 
65)*. *The topmost solid line is the estimate number of healthy persons when all were healthy at age 65, and the lower solid 
line is the number sick when all were healthy at age 65. The two dashed lines represent the number healthy and sick when all 
were sick at age 65. A third pair of dotted lines represent the number healthy and sick when 80% were healthy at baseline.
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Safety intervention is never the best. Table 4 is correct for
all values of α and λ, but does not permit assessment of
the combined interventions.
Another important consideration is the cost of imple-
menting and maintaining the interventions. This requires
specifying the cost of an intervention that improves a tran-
sition probability by 100*α% (or the cost of making
100*λ% of the sick persons healthy at baseline). In
Appendix 3 we show that under some assumptions, one
intervention is cost-effective relative to another interven-
tion if the ratio of their costs is lower than the inverse of
the ratio of their required α. As we have no information
about the costs of these hypothetical interventions, fur-
ther discussion of cost-effectiveness is limited to the exam-
ples in the discussion section.
Discussion
This paper makes several contributions to the literature.
We conceptualized the population as a system with three
(or more) health states. Because the only way to alter a
system is to change the initial conditions or the transition
probabilities, all public health interventions must make
one or more of these changes. This allows us to categorize
types of interventions and compare them in a systematic
manner. We incorporated β, the relative worth of an addi-
tional year of sick life, into the calculations and found it
to be influential in determining the relative performance
of various interventions. By standardizing the outputs of
all interventions to the One-Shot intervention, we
obtained a fair comparison of the different interventions.
And finally, we found that the amount of improvement in
YHL, YSL, and YOL is a linear function of α through the
origin (for |α| <0.3), which allowed us to calculate multi-
state life tables for only a few cases but to extend the
results to many other situations.
Multi-state life table methods have been used elsewhere to
estimate the consequences of modifying the transition
probabilities, decreasing the prevalence of certain diseases
or causes of death, or of meeting the healthy People 2000
objectives, on mortality and morbidity [14-23] and med-
ical expenditures [24]. This literature usually involves
only older adults (65 or older), and does not deal specifi-
cally with the type of interventions that might achieve
such changes.
Table 3: Improvements in Outcomes for the Interventions (10% improvement)
12 3 4 5 6 7
Intervention dYHL dYSL dYOL d$ Worth (β = .5) Required α
Birth cohort
Status Quo 00 0 0 0
One-Shot 0.067 -0.009 0.059 -122 0.0625 0
HP/DP 1.098 -0.700 0.398 -1283 0.7480 0.0084
Treatment 0.857 -0.555 0.303 -1070 0.5795 0.0108
ICU 0.334 0.258 0.592 4943 0.4630 0.0135
Safety 0.368 0.119 0.486 3404 0.4275 0.0146
HP/DP + One-Shot 1.166 -0.710 0.456 -1407 0.8110 0
HP/DP + ICU 1.420 -0.464 0.956 3352 1.1880 0.0053
Retiree cohort
Status Quo 0 0 0 0 0.0000
One-Shot 0.535 -0.234 0.301 -2 0.4180 0
HP/DP 0.485 -0.252 0.233 -8 0.3590 0.1164
Treatment 0.346 -0.178 0.167 6 0.2570 0.1626
ICU 0.197 0.222 0.420 4079 0.3080 0.1357
Safety 0.237 0.092 0.329 2676 0.2830 0.1477
HP/DP + One-Shot 1.041 -0.497 0.544 -8 0.7925 0
HP/DP + ICU 0.677 -0.046 0.632 3846 0.6540 0.0639
Columns:
1: Name of intervention
2: dYHL=YHL for the row intervention minus YHL for the Status Quo
3: dYOL=YOL for the row intervention minus YOL for the Status Quo
4: dYSL=YSL for the row intervention minus YSL for the Status Quo
5: d$ = Total medical expenditures for the row intervention minus expenditures for the Status Quo.
6: Incremental worth-adjusted years of life (worth) of the row intervention minus worth of the Status Quo, calculated as dYHL + .5*dYSL.
7: Level of α required for the row intervention to provide as much incremental worth as the One-Shot intervention, calculated as the column 6 
entry for One-Shot divided by the column 6 entry for the row intervention, multiplied by 0.10.BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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General features of the interventions are described next,
followed by some specific examples that illustrate the use
of this material.
Features of the Interventions
Figures 2 and 3 show that in this country there may be lit-
tle room for improvement of either the transition proba-
bilities or the initial conditions under age 40. It will be
more effective to target the health of middle-aged and
older adults, or subsets of the younger population where
the prevalence of sickness and the probability of becom-
ing sick or dying are higher. All interventions improved
YHL and YOL, but interventions that aimed to increase
YOL also increased morbidity and medical expenditures.
Table 4 shows which types of intervention are most effec-
tive, and also how strongly this conclusion depends on π
and β.
The One-Shot intervention is equivalent to replacing the
dashed lines in Figure 3 with the solid lines (making all
the sick persons healthy at baseline). The area between the
topmost solid and dashed curves in Figure 3 (multiplied
by the proportion of Birth cohort who are initially sick) is
the additional YHL associated with the One-Shot inter-
vention. Clearly, the effect of One-Shot on YHL is short-
term, and is small if there are few sick persons at baseline.
One-Shot thus performs better in the Retiree cohort (see
Figure 4). The effect of making only half of the sick per-
sons healthy at baseline (λ = .5) can be obtained by halv-
ing the values for One-Shot in Table 3.
The HP/DP, Treatment, and One-Shot interventions work
by keeping or making more persons healthy, thus directly
improving YHL and YSL. They indirectly improve YOL
because healthy persons have a lower mortality rate. The
ICU intervention keeps sick persons from dying, thus
directly increasing YOL and YSL, and indirectly increasing
YHL because persons saved from death may later become
healthy. The Safety intervention directly increases YOL
and YHL, but also somewhat surprisingly increases YSL,
because the persons saved by the intervention then live
long enough to accumulate YSL instead of dying young.
The net effect of these considerations is that the former
three interventions decrease medical expenditures, while
the latter two increase them.
The two combined interventions performed differently.
The worth of HP/DP + One-Shot (0.7925 in the Retiree
Table 4: Which Simple Intervention* achieves the same Worth as One-Shot with the smallest α for different initial conditions and 
values of β
Proportion Healthy at Baseline, π
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Birth cohort
β =  0 HHHHHHHHHH
0 . 1 HHHHHHHHHH
0 . 2 HHHHHHHHHH
0 . 3 HHHHHHHHHH
0 . 4 I HHHHHHHHH
0 . 5 I HHHHHHHHH
0 . 6 IIIIHHHHHH
0 . 7 IIIIIIHHHH
0 . 8 IIIIIIIIII
0 . 9 IIIIIIIIII
1 . 0 IIIIIIIIII
Retiree cohort
β =  0 TTTTHHHHHH
0 . 1 TTTTHHHHHH
0 . 2 TTTTHHHHHH
0 . 3 TTTTHHHHHH
0 . 4 IIIIIIHHHH
0 . 5 IIIIIIIIH H
0 . 6 IIIIIIIIH H
0 . 7 IIIIIIIIIH
0 . 8 IIIIIIIIII
0 . 9 IIIIIIIIII
1 . 0 IIIIIIIIII
* H is HP/DP, T is Treatment, I is ICU, and S is Safety (never the best). The parameter π is the baseline proportion healthy, and β is the relative 
worth of a year of sick life. For example, if π = .8 and β = .5, in the Retiree cohort the HP/DP intervention had the lowest required α, as was also 
seen in column 7 of Table 3.BMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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cohort) was slightly better than the sum of the worth of
HP/DP and One-Shot separately (0.3590+0.4180 =
0.7770). This apparent synergy may occur because the two
interventions act on different parts of the distribution,
with One-Shot initially increasing the number of healthy
persons for the HP/DP intervention to keep healthy. The
HP/DP + ICU intervention provided slightly less worth
than the sum of its components, possibly because the HP/
DP intervention kept people healthy, leaving the ICU
intervention with fewer sick persons to save from death.
HP/DP+ICU increased medical expenditures even though
it decreased YSL, apparently because it made relatively
large changes in YOL but relatively small decreases in YSL.
It is easy to evaluate the addition of One-Shot to the TX,
Safety, and ICU interventions, as explained in Appendix 2.
We presented only HP/DP + ICU in Tables 2 and 3
because it was better than the other combinations (for β =
.5). Combining different interventions would require
additional life table calculations.
It is possible to improve the estimates of the transition
probabilities and initial conditions, at least in the U.S.,
where many public population-based longitudinal data-
sets that ascertain death are available for subpopulations
of interest. We are not aware of any source for β, the rela-
tive worth to society of an additional year of sick life. This
information is needed because the choice of the best inter-
vention is sensitive to β. There is evidence that β < 1
because we invest in treatments for health problems that
are not life-threatening. Recent public discussions about
assisted suicide and withdrawal of life support from per-
sons in a persistent vegetative state suggest that β > 0. As
suggested in Table 4, the usual public health emphasis on
prevention programs makes an implicit assumption that β
< .798 in the Birth cohort and β < .606 in the Retiree
cohort; otherwise, public health would emphasize keep-
ing sick persons from dying (ICU), which provides the
most worth-adjusted years of life when β is large. We
showed results for β = .5, which was an arbitrary choice.
Interestingly, the method used by the National Center for
Health Statistics to calculate years of healthy life (by a dif-
ferent method from that reported here) are consistent
with a β of about .5 for older adults [25]. Further research
is needed in this area.
As discussed in Appendix 3, costs of the interventions are
crucial for decision making, but they are not known or
obvious for the hypothetical interventions we have con-
sidered. When these costs are known, the least expensive
intervention in column 7 of Table 3 would be the most
cost-effective.
Examples
Here we present examples that use the information in
Tables 2 and 3 under the standard parameter configura-
tion (λ = 1, α = .1, β = .5, π = .98 and .80), and also for
some different parameter values. (Appendix 2 explains the
calculations for other parameter values).
Suppose that a public health department could afford a
new program either to (A) make half of the sick 65-year-
olds healthy immediately (One-Shot with λ = .5), or (B)
decrease the probability of becoming sick each year by 5%
in the Birth cohort (HP/DP with α = .05), and also assume
that β = .5. From Table 3, the worth of (A) is .4180* λ =
.2090 worth-adjusted years, and the worth of (B) is α/
.10*.7480 = .3740. Other things equal, option B would be
preferred. However, if instead π = .90 for Birth cohort and
π = .50 for the Retiree cohort, the worth of A and B would
be .5224 and .3728 respectively, and option A would be
chosen. Or, if β was 0.7 instead of 0.5, the worth would be
.1856 and .3042, and option B would be chosen. The
choice of intervention is sensitive to the parameter values.
We next consider an existing intervention, "Welcome to
Medicare" (WTM), which covers a one-time preventive
physical exam within the first six months of enrolment in
Part B. The exam includes a thorough review of the
enrollee's health, education and counseling about preven-
tive services such as screenings and shots, and referrals for
other care. This is similar to our HP/DP+One-Shot inter-
vention, where the population consists of all 65-year-olds
who elect Part B coverage. Here, λ is the proportion of the
sick persons who are returned to the healthy state at base-
line, and α is the subsequent decrease in the probability of
getting sick, due to the prevention. Table 3 shows that if λ
= 1 and α = .10 (if all of the initially sick enrollees become
healthy and the probability of becoming sick decreases by
10%), this would increase YHL by 1.041 years and
increase YOL by .544 years, while decreasing YSL by .497
years. There would be essentially no change in future
medical expenditures, even though enrollees would live
longer.
If the average incremental cost of the WTM program was
$1000 per person, the cost per year of life saved would be
$1000/.544 or about $2000 per additional year of life. If
WTM was less effective, with λ = .08 and α = .008, YOL
would increase by .021 years, and an additional year of
life would cost about $50,000, which is a common thresh-
old for cost-effectiveness. Under these assumptions, Wel-
come to Medicare is cost-effective for the configuration λ
= .08 and α = .008, and for larger values of either parame-
ter. It would be interesting to estimate these parameters
for persons with and without Part B coverage, to provide
further information about cost-effectiveness.
Modifying π permits assessment of natural interventions
such as a pandemic that sickened all newborns. Figure 3
(for all sick at birth, or π = 0) shows that the Birth cohortBMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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would return to its equilibrium number of healthy and
sick by about age 5. The area between the top solid and
dashed lines is the loss in YHL due to the pandemic. Using
the standard configuration for the other parameters, the
Status Quo would be 64.52 YHL (vs. 67.80 in Table 2 line
1), and 74.46 YOL (vs. 77.3). The effect of such a pan-
demic would thus be the loss of 3.28 years of healthy life
and 2.84 years of life. One-Shot is the best single interven-
tion, resulting in 3.14 additional worth-adjusted years if λ
= 1.0. A pandemic that sickened only half of the newborns
(π = .5) would decrease YHL by 1.61 years and YOL by
1.38 years.
The tabled results can also be used to estimate the effect of
"negative" interventions. For example, if the intervention
was a chronic illness that lowered the probability of recov-
ering from illness by 10% at all ages, that would be the
same as the Treatment intervention with α = -0.10, and
the effects of the various interventions would be the val-
ues in Table 3 (columns 2–4 and 6) multiplied by -1. For
the Birth cohort, this illness would decrease YHL by .858
years, increase YSL by .554 years, and decrease YOL by
.303 years.
The tabled results, and a spread sheet available from the
authors that allows for different parameter values, should
be useful in assessing other hypothetical or existing pro-
grams, or to consider the effect of modifying some of the
parameters. More complex models may be needed to
compare specific interventions.
Limitations
The interventions considered are of course unrealistic.
There are probably few interventions that affect only a sin-
gle transition probability, or that could achieve the same
improvement at all ages. A package of interventions
would likely be needed, perhaps varying with age. We
assumed that α was the same for each age, but the life
table calculations for age-varying values of α would be
straightforward. Only small values of α were considered,
but this may be appropriate. The examples are simplistic,
but suggest some applications of this work.
For simplicity, we considered only three health states, but
more complex models are possible. The states were
defined based on self-rated health, which has face validity
as an important descriptor of the health of a population,
and is a well known correlate of mortality and of most
other important health variables [26]. (The strong associ-
ation of self-rated health with mortality can be seen in Fig-
ures 1 and 2). The states could instead have been based on
other measures such as activities of daily living. If so, we
could have estimated active life expectancy rather than
years of healthy life [27]. The resulting three-state system
would have different transition probabilities and a differ-
ent initial distribution. The conclusions about the relative
performance of the different intervention types would
probably have been similar, but this must be verified else-
where.
We ignored gender and race, in the interest of simplicity.
Gender- or race-specific transition probabilities would
have resulted in different YHL, YSL, and YOL [28] but not,
we believe, in different findings about the relative behav-
ior of the interventions. As with all life table calculations,
the transition probabilities at later ages may not be appro-
priate for persons born today, and these estimates cannot
be exact.
Medical expenditures were estimated from a single year of
MEPS data, and were extrapolated for ages 85 to 100.
Small changes in expenditures in Table 3 are well within
the range of error. Some of the interventions affected life-
time medical expenditures. However, many of these sav-
ings (or additional expenditures) would disappear under
the traditional 3% discounting for costs accrued over
time. We have not examined whether d$ is linear in α
through the origin. If it is, then changes in medical expen-
ditures can also be predicted for many configurations.
In this paper, we must assume that the interventions do
not change the heterogeneity within the healthy and sick
states at each age, relative to the general population. The
small values of α that we used should minimize this prob-
lem. For larger values of α, heterogeneity may be a prob-
lem, requiring more complex models. Appendix 4
provides additional discussion of heterogeneity.
Conclusion
Although a good deal of research has considered the mor-
tality and disability patterns of cohorts, our paper may be
the first to present transition probabilities across the
entire age range, and to examine the effects of specific
types of interventions on years of healthy life. Some
insights have been gained as to how different interven-
tions work to improve the health of the public. Health
promotion and disease prevention strategies had favora-
ble performance under most conditions, but ICU and
Treatment were sometimes better. The Safety intervention
would be implemented by passing and enforcing laws,
rather than by intervening directly on healthy and sick
persons. It might be cost-effective relative to the other
interventions even though it was never selected in Table 4.
The importance of β suggests that it is time for a national
discussion of the value to society of an intervention that
increases survival by increasing morbidity.
The small number of sick persons at any age is a tribute to
today's public health strategies. These results suggest how
the situation might be improved further by appropriateBMC Public Health 2007, 7:52 http://www.biomedcentral.com/1471-2458/7/52
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public health intervention strategies, especially at older
ages.
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